fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Baricitinib

All products: Limited Use (codes 734)

Olumiant · DIN 02544768 · 4 mg · tablet

Limited Use, Reason for Use code 734 requiredMarketed · checked November 17, 2026
StatusLimited Use, Reason for Use code 734 required
Write on scriptReason for Use code 734 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 734
Reason for Use code 734 Initiation criteria: For the treatment of adult patients with severe alopecia areata (AA) who meet the following criteria: 1. Have a Severity of Alopecia Tool (SALT) score of 50 or above, and 2. Have experienced the current episode of AA for more than 6 months but less than 8 years. The maximum duration of initial authorization is 36 weeks. Renewal criteria: For continuation of reimbursement, the patient must demonstrate beneficial clinical effect, defined as achieving a SALT score of 20 or less at 36 weeks after treatment initiation. Maintenance of a SALT score of 20 or less every 12 months thereafter is required for reimbursement renewal. Dosing and prescribing: The recommended dose is 2mg once daily. The maximum funded dose is 4mg once daily. Baricitinib should be prescribed by a dermatologist with expertise managing patients with severe AA. Baricitinib should not be used in combination with other JAK inhibitors, biologic immunomodulators, or systemic immunosuppressants. Coverage limit: LU Authorization Period: 1 year
No interchangeable product listed in the Ontario extract
Olumiant · DIN 02544768 Manufacturer: Eli Lilly Canada Inc.; listing date 2025-12-30 Health Canada: Marketed since 2024-04-09 · brand OLUMIANT · ATC L04AF02 BARICITINIB · form Tablet · route Oral · ingredients BARICITINIB 4 MG · company Eli lilly canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Olumiant: Formulary list price $59.44 per unit (the source does not state the unit; exact figure $59.4367). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02544768)

Source record
DIN 02544768: Olumiant Raw flags: sec12=Y, sec3=Y Item: 924400021; group id 1049; item number 2405; lccId 00422; manufacturer id LIL Source form: Tab; strength: 4mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $59.4367; ministry $59.4367 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02544768 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103336
Shortage status: not checked (no credentials)

Other products in the same Health Canada class (L04A): coverage varies; not interchangeable

  • Tacrolimus (Envarsus PA): limited Use 590
  • Cladribine (Mavenclad): not a benefit
Other drugs in the same formulary class (92:44 Immunosuppressive Agents) and how they are covered

Matched class: 92:44 Immunosuppressive Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over No displayed product is listed as a general benefit in this extract. Check its listing requirements below. 92:44 Immunosuppressive Agents

TACROLIMUS

· 3 products · Limited Use, codes 590 · strengths: 0.75mg, 1mg, 4mg · ER Tab

CLADRIBINE

· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 10mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 92:44
Full class listing Related classes: 92:20 Biologic Response Modifiers, 92:36 Disease-Modifying Antirheumatic Agents, 92:92 Other Miscellaneous Therapeutic Agents Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: rheumatoid arthritis
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. ADALIMUMAB · Limited Use, codes 600, 601, 602, 603, 604, 605, 606, 607, 609, 611 (23), Limited Use, codes 600, 602, 603, 604, 605, 606, 607, 609, 633, 634 (7) Indications AMGEVITA is indicated for: Rheumatoid Arthritis • reducing the signs and symptoms, inducing major clinical response and clinical remission, inhibiting the progression of structural damage and improving physical function in adult patients with moderately to severely active rheumatoid arthritis (RA). PM: https://pdf.hres.ca/dpd_pm/00085868.PDF; date not captured; DIN 02459299; fetched 2026-09-10 Product monograph METHOTREXATE · General benefit (29), Listed, not a benefit (1), Off-Formulary Interchangeable, not an ODB benefit (4) • Severe disabling rheumatoid arthritis (RA) PM: https://pdf.hres.ca/dpd_pm/00078227.PDF; date JAN 08, 2025; DIN 02170698; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-09-22
What the Health Canada label says it is for
1 INDICATIONS OLUMIANT (baricitinib tablets) is indicated for: Rheumatoid Arthritis (RA) • In combination with methotrexate (MTX), for reducing the signs and symptoms of moderate to severe rheumatoid arthritis (RA) in adult patients who have responded inadequately to one or more disease-modifying anti-rheumatic drugs (DMARDs). OLUMIANT may be used as monotherapy in cases of intolerance to MTX. Limitations of Use: Use of OLUMIANT in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine is not recommended (see 7 WARNINGS AND PRECAUTIONS, Immune). Alopecia Areata (AA) OLUMIANT is indicated for the treatment of adult patients with severe alopecia areata. Limitations of Use: Use of OLUMIANT in combination with other JAK inhibitors, biologic immunomodulators, or with potent immunosuppressants such as azathioprine and cyclosporine is not recommended (see 7 WARNINGS AND PRECAUTIONS, Immune). 1.1 Pediatrics Pediatrics (<18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics Geriatrics (≥ 65 years of age): Cau… https://pdf.hres.ca/dpd_pm/00074394.PDF PM date: not printed or not captured Source product: OLUMIANT; DIN 02480018; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
Program rules and quotes
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules): ODB 65 and over (seniors path) Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗) Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗) Eligibility: Individual annual net income threshold Program year August 1, 2026 to July 31, 2027: $25,480 This applies to a senior who: does not have a spouse has a married spouse with whom they no longer live in a conjugal relationship has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗) Eligibility: Combined annual net income requirement Program year August 1, 2026 to July 31, 2027: $42,290 This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗) Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗) What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗) What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗) What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗) Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗) Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100. That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year). For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25. Use this chart below to see what the deductible will be in your first year:
Month you were bornAmount of first-year deductible
July$100.00
August$91.67
September$83.33
October$75.00
November$66.67
December$58.33
January$50.00
February$41.67
March$33.33
April$25.00
May$16.67
June$8.33

Ontario source · 2026-08-18